So January and February I got a lot of migraines. A lot. I don’t know why I’m getting so many. I guess I can be grateful that many of them are not severe.

Here’s a round-up of articles on migraine research that made me feel better than that graph:

• A nice summary of migraine and recent research with a strong focus on neuroanatomical findings (what’s up with those white lesions?) in New Scientist. [PDF]
• Teva (the company that makes frovatriptan) is working on a CGRP monoclonal antibody. It’s working for both chronic and high frequency episodic migraine in phase II clinical trials.
• Teva isn’t the only company with a horse in this race. There are at least three other CGRP monoclonal antibodies in development to target the CGRP pathway.